Engineered immune cells take aim at Hard-to-Treat lupus
NCT ID NCT06897930
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study tests a new treatment called AZD0120 for people with severe lupus that hasn't improved with standard therapies. AZD0120 is a type of CAR T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to calm the overactive immune system. The trial will enroll 150 adults and first check safety and dosing, then measure how well it controls lupus symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGSan Francisco, California, 94143, United States
-
Research Site
NOT_YET_RECRUITINGStanford, California, 94304-2201, United States
-
Research Site
SUSPENDEDTampa, Florida, 33612, United States
-
Research Site
NOT_YET_RECRUITINGAtlanta, Georgia, 30322, United States
-
Research Site
NOT_YET_RECRUITINGChicago, Illinois, 60611, United States
-
Research Site
WITHDRAWNBethesda, Maryland, 20892, United States
-
Research Site
RECRUITINGBoston, Massachusetts, 02115, United States
-
Research Site
NOT_YET_RECRUITINGSt Louis, Missouri, 63110, United States
-
Research Site
RECRUITINGNew York, New York, 10032, United States
-
Research Site
RECRUITINGSyracuse, New York, 13202-2240, United States
-
Research Site
NOT_YET_RECRUITINGChapel Hill, North Carolina, 27599-7280, United States
-
Research Site
RECRUITINGCharlotte, North Carolina, 28204, United States
-
Research Site
NOT_YET_RECRUITINGRichmond, Virginia, 23298, United States
-
Research Site
RECRUITINGSeattle, Washington, 98104, United States
-
Research Site
RECRUITINGSeattle, Washington, 98195, United States
-
Research Site
NOT_YET_RECRUITINGDarlinghurst, 2010, Australia
-
Research Site
NOT_YET_RECRUITINGMelbourne, 3000, Australia
-
Research Site
NOT_YET_RECRUITINGToronto, M5T 2S8, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD0120 (a dual-target CAR T cell therapy that attacks CD19 and BCMA proteins on immune cells)
What this could lead to
If successful, this could offer a new treatment option for people with severe lupus that hasn't responded to other therapies, potentially reducing disease activity without lifelong medication.
What could go wrong
This is an early-phase trial (1b/2) with only 150 participants, so results may not apply to all lupus patients. CAR T therapy carries risks like cytokine release syndrome and infections, and long-term safety is unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.